Abstract
Sixteen 2-cyclohexenone and 6-(ethoxycarbonyl)-2-cyclohexenone analogs of combretastatin-A4 (CA-4, 1) were synthesized, and their ability to inhibit the growth of two murine cancer cell lines (B16 melanoma and L1210 leukemia) was determined using an MTT assay. One of the cyclohexenone analogs, 8, which contains the same substituents as CA-4 (1) is the most potent (IC50 = 0.91 μM, L1210). Exposure of A- 10 aortic cells to cyclohexenone 8 and its ester congener 7 produced significant reduction in cellular microtubules, with EC50 values of 27 and 37 μM, respectively. Molecular modeling studies indicate that analog 8 adopts a twisted conformation, similar to CA-4, suggesting that conformation and structure are crucial for activity. These compounds are worthy of further investigation as potential tubulin inhibitors in the quest for novel anti-cancer agents.
Keywords: Combretastatin-A4, Tubulin, Anticancer, Cyclohexenone, Cytotoxicity, Synthesis
Letters in Drug Design & Discovery
Title: Design, Synthesis and Biological Testing of Cyclohexenone Derivatives of Combretastatin-A4
Volume: 4 Issue: 2
Author(s): Jennifer Ruprich, Andrew Prout, John Dickson, Brent Younglove, Lawrence Nolan, Khyati Baxi, Regan LeBlanc, Lori Forrest, Patrice Hills, Herman Holt Jr, Hilary Mackay, Toni Brown, Susan L. Mooberry and Moses Lee
Affiliation:
Keywords: Combretastatin-A4, Tubulin, Anticancer, Cyclohexenone, Cytotoxicity, Synthesis
Abstract: Sixteen 2-cyclohexenone and 6-(ethoxycarbonyl)-2-cyclohexenone analogs of combretastatin-A4 (CA-4, 1) were synthesized, and their ability to inhibit the growth of two murine cancer cell lines (B16 melanoma and L1210 leukemia) was determined using an MTT assay. One of the cyclohexenone analogs, 8, which contains the same substituents as CA-4 (1) is the most potent (IC50 = 0.91 μM, L1210). Exposure of A- 10 aortic cells to cyclohexenone 8 and its ester congener 7 produced significant reduction in cellular microtubules, with EC50 values of 27 and 37 μM, respectively. Molecular modeling studies indicate that analog 8 adopts a twisted conformation, similar to CA-4, suggesting that conformation and structure are crucial for activity. These compounds are worthy of further investigation as potential tubulin inhibitors in the quest for novel anti-cancer agents.
Export Options
About this article
Cite this article as:
Ruprich Jennifer, Prout Andrew, Dickson John, Younglove Brent, Nolan Lawrence, Baxi Khyati, LeBlanc Regan, Forrest Lori, Hills Patrice, Holt Jr Herman, Mackay Hilary, Brown Toni, Mooberry L. Susan and Lee Moses, Design, Synthesis and Biological Testing of Cyclohexenone Derivatives of Combretastatin-A4, Letters in Drug Design & Discovery 2007; 4 (2) . https://dx.doi.org/10.2174/157018007779422442
DOI https://dx.doi.org/10.2174/157018007779422442 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology Apoptosis-Induction is A Novel Therapeutic Strategy for Gastrointestinal and Liver Cancers
Current Gene Therapy Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Ras-Induced Senescence and its Physiological Relevance in Cancer
Current Cancer Drug Targets Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry Chemokines as Therapeutic Targets in Non-Small Cell Lung Cancer: Update
Medicinal Chemistry Reviews - Online (Discontinued) Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) Recent Advances in Intervention in Markovian Regulatory Networks
Current Genomics Modulation of Human Keratinocyte Responses to Solar UV by Plant Polyphenols As a Basis for Chemoprevention of Non-Melanoma Skin Cancers
Current Medicinal Chemistry Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Current Pharmaceutical Design Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening Synthesis of Combretastatin A-4 Analogs and their Biological Activities
Anti-Cancer Agents in Medicinal Chemistry Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Costimulation, Coinhibition and Cancer
Current Cancer Drug Targets